EktaH pushes experimental obesity drug NKS-3 into Phase II, bags €2.4 million funding
By: IPP Bureau
Last updated : November 18, 2026 2:13 pm
First patient enrolled in Phase IIa trial in Tunisia as French biotech company prepares larger clinical programme targeting weight loss
French biotechnology company EktaH has advanced its experimental obesity treatment, NKS-3, into Phase II clinical development, marking a significant step in its effort to develop a new oral therapy for obesity and metabolic diseases.
The company has also secured €2.4 million in non-dilutive funding from French public investment bank Bpifrance to accelerate the drug's clinical development, including preparations for a larger Phase II trial in France.
The first patient has been recruited for the exploratory Phase IIa SERENITY-1 clinical trial, which is underway in Tunisia. The study will assess the drug's potential to reduce body weight and examine its effects on fat mass, muscle preservation and safety.
The development comes as pharmaceutical companies intensify efforts to find new approaches to obesity treatment, particularly alternatives and potential complementary therapies to existing GLP-1-based drugs.
The randomized, single-blind, placebo-controlled SERENITY-1 study is being conducted at the Institut National de Nutrition de Tunis and is expected to enrol approximately 31 adults with obesity.
Participants will be assigned in a 2:1 ratio to receive either NKS-3 or a matching placebo. The treatment will be self-administered for 90 days at a dose of 7.5 mg twice daily.
The primary endpoint is the percentage change in body weight from baseline to Day 90.
Researchers will also assess changes in sensitivity to linoleic acid, the safety and tolerability of the treatment, and the composition of weight loss, including changes in fat mass and skeletal muscle mass.
Topline results from the trial are expected in the first quarter of 2027.
The €2.4 million funding package from Bpifrance will support several critical development activities, including a 90-day toxicology study, chemistry, manufacturing and controls (CMC) work, and further clinical trials.
The funding will be released in stages, subject to annual development milestones and regulatory progress. It comprises an equal combination of grant funding and reimbursable advances.
EktaH is also preparing an expanded Phase II programme using a new formulation of NKS-3. The programme will examine two potential applications: weight loss as a standalone treatment and weight maintenance following the discontinuation of GLP-1 therapy.
The planned multicentre, randomized, dose-finding studies will investigate whether NKS-3 can reduce body weight and fat mass while preserving lean muscle.
A key focus will be whether the drug can help patients maintain weight loss after stopping GLP-1 treatment. The possibility is supported by preliminary preclinical findings, although its effectiveness in humans remains to be established through clinical trials.
One planned study is expected to involve approximately 100 adults with obesity, comparing two NKS-3 dosing regimens against placebo. Participants will receive treatment for 12 weeks, followed by a further 12-week period without treatment to assess longer-term effects.
The final trial designs will depend on regulatory and ethics approvals.
EktaH aims to submit its Clinical Trial Application in early 2027, with the first patient expected to be enrolled in the second half of that year.
“Advancing NKS-3 into Phase II clinical development marks an important milestone for EktaH,” said Xavier Boidevezi, CEO and Co-founder of EktaH. “With the SERENITY-1 study now recruiting patients in Tunisia and Bpifrance funding supporting preparations for a larger Phase II study in France, we are progressing a clinical development program designed to further evaluate the efficacy, safety and therapeutic potential of our differentiated approach to obesity treatment.”
Meanwhile, EktaH is nearing completion of its Phase I clinical study, with the database expected to be locked by the end of November 2026. Final results and the Clinical Study Report are anticipated in Q1 2027.
The randomized, single-blind, placebo-controlled, single-centre study enrolled 120 adults with obesity across single- and multiple-ascending-dose cohorts.
It evaluated NKS-3 and NKS-5, two modified linoleic acids, examining their safety and potential effects on body weight and oral fat sensitivity.
Preliminary data from 22 participants who received NKS-3 for 30 days have shown no serious adverse events considered related to the drug reported to date.
The full analysis is expected to provide a more comprehensive picture of the compounds' safety and preliminary efficacy, helping guide the next phase of clinical development.
NKS-3 is an oral modified fatty acid designed to reactivate two fat taste receptors, CD36 and GPR120, in the tongue epithelium. These receptors are downregulated in many individuals with obesity.
EktaH's approach is to restore the activity of these receptors and stimulate the body's natural production of appetite-regulating hormones, including GLP-1, cholecystokinin (CCK) and peptide YY (PYY).
Unlike treatments that administer hormones externally, NKS-3 is designed to activate the body's own satiety-signalling pathways, potentially helping reduce food intake through endogenous hormonal responses.
The company's preclinical research has also raised the possibility of using NKS-3 to tackle weight regain after GLP-1 treatment.
In studies involving diet-induced obese mice, animals receiving NKS-3 after discontinuing semaglutide experienced approximately 50% less weight rebound than control animals, while preserving lean body mass.
However, these findings are based on animal studies and have yet to be validated in human clinical trials.
Beyond obesity, NKS-3 has demonstrated anti-inflammatory activity in multiple experimental models, with reductions in key pro-inflammatory cytokines and changes in central inflammatory signalling pathways.
EktaH believes these findings could open another development opportunity, potentially extending the compound's application to the broader inflammatory processes associated with obesity and metabolic diseases.